Value-Based Medicine News

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).

Michael A. Choti, MD, MBA, Banner MD Anderson, cochaired the second annual Advancing Value-Based Oncology Care meeting and shared insights into the goals of this year's event and value-based medicine as a whole.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses highlights of the Institute for Value-Based Medicine® (IVBM) event, held in partnership with Providence Health System, that recently took place in Newport Beach, California.

Jennifer Sturgill, DO, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact on heart failure care of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 under the Inflation Reduction Act (IRA).

Fee-for-service care is not really in line with how primary care physicians think or how primary care should be delivered; the crux of value-based care is wanting patients to have the care they want and need, noted Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care.

In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.

Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, co-presented “Value-Based Care: What Is It and Why Should We Care?” at our most recent Institute for Value-Based Medicine® event with the Zangmeister Cancer Center of Columbus, Ohio, on September 14.

Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care, spoke at our recent Institute for Value-Based Medicine® event held with Zangmeister Cancer Center. Here, she addresses the importance of value-based care within the primary care space.

In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.

Susan Spratt, MD, senior medical director, Duke Population Health Management Office, breaks down the the prevalence of diabetes in the United States and discusses current diabetes initiatives at Duke Health.

Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology, discusses how collaboration between oncologists and primary care physicians (PCPs) can improve patient satisfaction and outcomes.

Telehealth provides more flexibility for patients with gastrointestinal issues to better fit their care into their lives and around symptoms they may be experiencing, said Sam Holliday, co-founder and CEO of Oshi Health.

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Guideline-directed cancer care—with help from a clinical support tool—can close disparities while reducing costs more efficiently than other means, such as prior authorization.

Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.

Ishani Ganguli, MD, MPH, assistant professor of medicine at Harvard Medical School, physician at Brigham and Women’s Hospital, reacts to receiving the 2022 Seema S. Sonnad Emerging Leader in Managed Care Research Award.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

The Enhancing Oncology Model (EOM) will be the successor to the Oncology Care Model.

Co-hosted by Memorial Sloan Kettering Cancer Center, the most recent Institute for Value-Based Medicine® event took place on September 22, with a focus on improving cancer care delivery through innovation.

Ty J. Gluckman, MD, FACC, FAHA, who is medical director of the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, addressed the 2022 Congress of the American Society for Preventive Cardiology meeting in Louisville, Kentucky.

At a panel for the National Health Alliance, 3 experts talked about incorporating patient needs and requests in cancer care.

Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.

Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.

The administration said it would make the results of its drug price negotiations with manufacturers, as well as its approach to value-based care models, open to a variety of payers.